Download MP4 Video Faculty: Robert Henry, MD

 Robert Henry, MD, from the VA Medical Center in San Diego, California, reviews the basic physiology behind a potential new class of diabetes drug, sodium glucose co-transporter-2 (SGLT-2) inhibitors, and their potential in the future treatment of type 2 diabetes.  

Subscribe to our video podcast: Itunes Logo 20